Leishmaniasis Treatment Market Size, Segmentation and Competitors Analysis 2020-2027

1
Leishmaniasis Treatment Market To Reach USD 206.5
Million by 2026
www.reportsanddata.com
sales_at_reportsanddata.com
2
Market Summary
High prevalence of target diseases in rural and
developing nations, increased prevalence of
malnutrition across the globe, lack of hygiene
and poor sanitation facilities, Migratory
patterns of population, introduction of new
chemical entity in the field of therapeutics,
favorable government regulations, and increased
RD investments are key factors contributing to
high CAGR of point of care diagnostics market
during the forecast period. Leishmaniasis
Treatment Market Size USD 104.8 Billion in
2018, Market Growth - CAGR of 8.8, Market
Trends introduction of new chemical entity in
the field of therapeutics, increased RD
investments
3
Our Approach
Market Summary

• According to the current analysis of Reports and
  Data, the global Leishmaniasis Treatment market
  was valued at USD 104.8 million in 2018 and is
  expected to reach USD 206.5 million by the year
  2026, at a CAGR of 8.8. A disease outbreak takes
  place when a disease escalates by a higher number
  than expected in a region or during a season. An
  outbreak may occur in one community or even
  extend to several countries altogether. There was
  a time when people in all countries and on all
  continents remain chronically vulnerable to
  infectious diseases, known and unknown.
  Leishmaniasis was the neglected tropical disease
  (NTD) that has threatened the people worldwide as
  per the WHO. Leishmaniasis is a major complex of
  protozoal vector-borne diseases that affects both
  humans and animals. The disease is caused by
  different species of Leishmania, and it is
  manifested by three major clinical forms named as
  cutaneous, mucosal and visceral leishmaniasis.
  Leishmaniasis is transmitted by the bite of
  infected female sand flies. In each of these
  forms, infection ranges from causing no symptoms
  (asymptomatic infection) to severe, even
  life-threatening complications.
• Key participants Sanofi S.A., Sequus
  Pharmaceuticals Inc., Paladin Labs Inc., Enzon
  Pharmaceuticals Inc., Gland Pharma Limited,
  Gilead Life sciences and Lifecare Innovations
  Private Limited.
• To Get Sample Copy of Report visit
  https//www.reportsanddata.com/sample-enquiry-form
  /2153

4
Our Approach
Market Summary

• Disease Type (Revenue, USD Million 20162026)
• Cutaneous Leishmaniasis
• Diffuse Cutaneous Leishmaniasis
• Mucocutaneous Leishmaniais
• Mucosal Leishmaniasis
• Visceral Leishmaniasis
• Pathological tests (Revenue, USD Million
  20162026)
• By Serological Tests
• Parasitological Evaluation
• DNA- Based Methods
• Immunological Methods
• Others
• Grab Your Report at an Impressive Discount!
  Please Click Here _at_ https//www.reportsanddata.com
  /discount-enquiry-form/2153

5
Our Approach
Market Summary

• Therapy type (Revenue, USD Million 20162026)
• By Drug Therapy
• Pentavalent Antimonials
• Sodium Stibogluconate
• SSG Meglumine antimoniate
• Antifungal
• Antibiotics
• By Non-Drug Therapy
• End Use Revenue, USD Million 20162026)
• Hospitals
• Clinics
• Diagnostic Laboratory
• Others

6
Our Approach
Market Summary

• Further key findings from the report suggest
• Introduction of new chemical entity will drive
  the leishmaniasis treatment market. According to
  the data of Drugs for Neglected Diseases
  initiative (DNDi), in 2017 two new chemical
  entities labelledDNDI-6148 and DNDI-0690 are
  introduced into the preclinical development stage
  to treat visceral and cutaneous leishmaniasis in
  2016. Immunomodulator- CpG-D35, is also in a
  pre-clinical development stage, which would
  further be used as an adjunct along with main
  drug therapy to treat cutaneous leishmaniasis.
  These technical advances have the potential to
  transform new treatment therapy in upcoming
  future, in turn driving the growth of
  leishmaniasis treatment market during the
  forecast period.
• In the pathological testing segment, serological
  testing is expected to be the fastest growing
  segment which is expected to grow at a CAGR of
  9.4 during the forecast period due to the global
  rise in the infectious disease outbreaks
  including include Leishmaniasis in developing
  nations. The outbreak of epidemic disease due to
  the malnutrition, population displacement, poor
  housing, a weak immune system and lack of
  financial resources are responsible for the
  market growth across the globeContinued
• Access the Entire Report packed with TOC, Tables
  and Figures and Outline of Prominent Companies _at_
  https//www.reportsanddata.com/report-detail/leish
  maniasis-treatment-market

7
Our Approach
About Us

• Reports and Data is a market research and
  consulting company that provides syndicated
  research reports, customized research reports,
  and consulting services. Our solutions purely
  focus on your purpose to locate, target and
  analyze consumer behavior shifts across
  demographics, across industries and help clients
  make a smarter business decision. We offer market
  intelligence studies ensuring relevant and
  fact-based research across a multiple industries
  including Healthcare, Technology, Chemicals,
  Power, and Energy. We consistently update our
  research offerings to ensure our clients are
  aware about the latest trends existent in the
  market. Reports and Data has a strong base of
  experienced analysts from varied areas of
  expertise.
• Contact Us
• John Watson
• Head of Business Development
• Reports And Data Web www.reportsanddata.com
• Direct Line 1-212-710-1370
• E-mail sales_at_reportsanddata.com